



Teresa Bitetti

**President, Global
Oncology Business Unit**

Teresa Bitetti is President of the Global Oncology Business Unit and a member of the Executive Team at Takeda, where she oversees a global portfolio of therapies targeting gastrointestinal, thoracic, and hematological cancers. In this role, Teresa leads all aspects of Takeda's multi-billion-dollar oncology business, with major markets in the US, Europe, and Japan.

With a proven track record in product development, launch excellence, and successful commercialization, Teresa is recognized for her ability to drive product growth in both emerging and mature markets. Her leadership has been instrumental in launching blockbuster medicines and in inspiring and mobilizing teams to deliver exceptional performance. Teresa's commercial expertise and experience building and accelerating pipelines has consistently delivered value for patients.

Since joining Takeda, she has led the launch of a medicine for patients with previously treated metastatic colorectal cancer, and secured approvals for Takeda Oncology therapies in new indications in lymphoma, leukemia, and lung cancer. Her strategic vision has strengthened Takeda's oncology portfolio through the execution of impactful business development partnerships and close collaboration with R&D to translate scientific discoveries into meaningful therapies.

Before joining Takeda, Teresa was Senior Vice President and Head of Worldwide Oncology Commercialization at Bristol Myers Squibb (BMS). At BMS, she was pivotal in launching the blockbuster lung cancer treatment Opdivo, accelerating the oncology pipeline and developing the long-term strategy for the immuno-oncology portfolio. Her experience at BMS also included leadership roles in infectious diseases and neuroscience, where she successfully launched the blockbuster medicine Abilify. While at BMS, she served as Senior Vice President and Head of U.S. Oncology, President and General Manager of BMS Canada, and Worldwide Head of BMS Virology. Prior to BMS, Teresa was part of the Capital Markets Group at Mobil Oil Corporation, overseeing the investment of Mobil's worldwide pension assets.

In addition to her role at Takeda, Teresa serves on the Board of Directors for Osmol Therapeutics, which is focused on developing a treatment to prevent chemotherapy-induced peripheral neuropathy. Teresa is also on the Board of Directors for Aura Biosciences, which is a biotech developing precision therapies for solid tumors designed to preserve organ function.

Teresa earned her MBA from the Darden School of Business at the University of Virginia and her BA from Wellesley College. She has two children and resides in Cambridge, Massachusetts.



ONCOLOGY